The effectiveness of cabergoline for preventing ovarian hyperstimulation syndrome in the ART cycle

DOI Web Site
  • MIYAKE Tatsuya
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine
  • TSUTSUI Tateki
    Department of Obstetrics and Gynecology, Japan Community Healthcare Organization (JCHO) Osaka Hospital
  • MASAKI Hidetake
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine
  • FUJIMORI Yuka
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine
  • GOA Satoko
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine
  • OHYAGI Chifumi
    Department of Obstetrics and Gynecology, Japan Community Healthcare Organization (JCHO) Osaka Hospital
  • KUMASAWA Keiichi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine
  • KIMURA Tadashi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine

Bibliographic Information

Other Title
  • ART治療における卵巣過剰刺激症候群に対するCabergolineの予防効果の検討
  • 症例報告 ART治療における卵巣過剰刺激症候群に対するCabergolineの予防効果の検討
  • ショウレイ ホウコク ART チリョウ ニ オケル ランソウ カジョウ シゲキ ショウコウグン ニ タイスル Cabergoline ノ ヨボウ コウカ ノ ケントウ

Search this article

Description

Ovarian hyperstimulation syndrome (OHSS) is characterized by enlarged ovaries, fluid shift to the third space, and hemoconcentration. Recent research findings have identified that a major contributory factor in OHSS is excessive secretion of vascular endothelial growth factor induced by human chorionic gonadotropin. In assisted reproductive technology (ART) treatment for a group of individuals at high risk of OHSS, we prevented OHSS by using gonadotropin-releasing hormone (GnRH) agonist as a trigger of ovulation, coasting, or embryo cryopreservation for future use with avoidance of embryo transfer in the same cycle. However, the effect appeared insufficient in some cases. Recently several reports have described the effect of cabergoline in preventing OHSS. In this study, we retrospectively examined the effect of cabergoline in preventing OHSS. We evaluated eight patients who were expected to develop OHSS caused by controlled ovarian stimulation during ART treatment. All retrieved oocytes were fertilized, and embryos of good quality were cryopreserved. Patients started seven-day treatment with oral cabergoline and progesterone the next day after oocyte retrieval. No patients developed moderate or severe OHSS, although five patients developed mild OHSS. Our findings suggest that administration of cabergoline is useful in preventing moderate or severe OHSS in ART treatment. [Adv Obstet Gynecol, 67 (3) : 270-275, 2015 (H27.8)]

Journal

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top